Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 4;405(10472):7-10.
doi: 10.1016/S0140-6736(24)02706-5. Epub 2024 Dec 12.

Regional action needed to halt antimalarial drug resistance in Africa

Rosario Martinez-Vega  1 , Deus S Ishengoma  2 , Roly Gosling  3 , Philip J Rosenthal  4 , Arjen Dondorp  5 , Karen I Barnes  6 , Christian Nsanzabana  7 , Abdoulaye A Djimde  8 , Lynette I Ochola-Oyier  9 , James Tibenderana  10 , John Chimumbwa  11 , Lemu Golassa  12 , Ntuli A Kapologwe  13 , Wilfred F Mbacham  14 , Moses R Kamya  15 , David A Fidock  16 , Ryuichi Komatsu  17 , Lorenz von Seidlein  5 , Mehul Dhorda  18
Affiliations

Regional action needed to halt antimalarial drug resistance in Africa

Rosario Martinez-Vega et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

DSI is a member of the PMI-supported Partnership for Antimalarial Resistance Monitoring in Africa Network (PARMA), the Genomic Epidemiology of Malaria Network (MalariaGEN), and the Pathogen Diversity Network Africa and is partly supported by the Bill & Melinda Gates Foundation (grant number INV 067322). RG reports support of salary from Unitaid as technical director of Plus Project, consulting fees from Population Services International and the University of California San Francisco, is a DSMB member of the mass R21 vaccine in Bangladesh for malaria elimination and multicentre study of ivermectin for scabies treatment (Mahidol Oxford Research Unit) and the TADORE dose finding study of tafenoquine for vivax malaria (Menzies University), and is the Director of the non-profit LEAD Ubuntu Global Foundation. PJR is a member of the World Health Organization Guideline Development Group for Malaria Chemotherapy. AD is the Chair of the Regional Steering Committee for the Regional Artemisinin-resistance Initiative from the Global Fund. KIB reports a grant paid to her institution from the European Union under the Global Health EDCTP3 Joint Undertaking (grant agreement no 101103076) as the Coordinator of Mitigating Antimalarial Resistance Consortium for SE-Africa (MARC SE-Africa). JC is the Executive Director of the SADC Malaria Elimination 8 Initiative. WFM and MRK are members of the PMI-supported Partnership for Antimalarial Resistance Monitoring in Africa Network (PARMA). DAF reports grants from the NIAID/NIH (R01 AI109023, R01 AI185559), and is a member of the Malaria Policy Advisory Group that advises to the Global Malaria Programme at the WHO. RK is the Chief Executive Officer of Navigo Partners, a consulting company currently conducting a review of ASEAN's 5 year health plan but with no engagement in the topic discussed in this Comment and was employed by the Global Fund before March, 2023. All other authors declare no competing interests. KIB coordinates the Mitigating Antimalarial Resistance Consortium in South-East Africa (MARC SE-Africa), funded by the EU under the Global Health EDCTP3 Joint Undertaking (grant agreement 101103076). The views and opinions expressed in this Comment are, however, those of the authors only and do not necessarily reflect those of the Global Health EDCTP3 Joint Undertaking nor its members; neither of the aforementioned parties can be held responsible for them. During the preparation of this Comment the authors used ChatGPT to reduce the character count in the title and the word count in the first paragraph. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

References

    1. Ishengoma DS, Gosling R, Martinez-Vega R, et al. Urgent action is needed to confront artemisinin partial resistance in African malaria parasites. Nat Med 2024; 30: 1807–08. - PubMed
    1. Rosenthal PJ, Asua V, Bailey JA, et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect Dis 2024; 24: e591–600. - PubMed
    1. Bjorkman A, Gil P, Alifrangis M. Alarming Plasmodium falciparum resistance to artemisinin-based combination therapy in Africa: the critical role of the partner drug. Lancet Infect Dis 2024; 24: e540–e41. - PubMed
    1. Dhorda M, Kaneko A, Komatsu R, et al. Artemisinin-resistant malaria in Africa demands urgent action. Science 2024; 385: 252–54. - PubMed
    1. Mlugu EM, Dondorp AM, Barnes KI. Resistant malaria parasites gaining momentum in Africa. Lancet Infect Dis 2024; 24: 1181–82. - PubMed

LinkOut - more resources